Get the Stockscreener App
0.429
0.28%
-0.0012
After Hours:
.42
-0.009
-2.10%
Femasys Inc stock is traded at $0.429, with a volume of 468.06K.
It is down -0.28% in the last 24 hours and down -24.49% over the past month.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
See More
Previous Close:
$0.4302
Open:
$0.4168
24h Volume:
468.06K
Relative Volume:
0.74
Market Cap:
$25.91M
Revenue:
$2.29M
Net Income/Loss:
$-18.63M
P/E Ratio:
-0.7635
EPS:
-0.5619
Net Cash Flow:
$-19.32M
1W Performance:
+7.79%
1M Performance:
-24.49%
6M Performance:
-22.08%
1Y Performance:
-62.53%
1-Day Range:
$0.41
$0.43
1-Week Range:
$0.371
$0.44
52-Week Range:
$0.3067
$1.29
Femasys Inc Stock (FEMY) Company Profile
Name
Femasys Inc
Sector
Industry
Phone
770-500-3910
Address
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
0.429 | 25.98M | 2.29M | -18.63M | -19.32M | -0.5619 |
ISRG
Intuitive Surgical Inc
|
468.36 | 165.94B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
155.52 | 44.30B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
80.73 | 38.96B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
47.93 | 38.69B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
228.80 | 33.61B | 5.40B | 1.49B | 1.78B | 10.12 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Initiated | Laidlaw | Buy |
Femasys Inc Stock (FEMY) Latest News
Weekly Trades: Is Femasys Inc stock undervalued right now2026 Review & AI Enhanced Execution Alerts - baoquankhu1.vn
Femasys (FEMY) Falls 27% as Firm to Raise $8-Million from Share Sale - MSN
Market Rankings: Can Femasys Inc sustain its profitabilityBond Market & Fast Moving Stock Trade Plans - baoquankhu1.vn
Femasys (NASDAQ: FEMY) targets reverse split and dilutive note, warrant share issuances - Stock Titan
Can Femasys Inc grow without external funding2026 Closing Moves & Advanced Technical Signal Analysis - baoquankhu1.vn
Femasys appoints John Canning as COO - MSN
Femasys Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
Lake Street Maintains Femasys(FEMY.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
Femasys names John Canning as chief operating officer By Investing.com - Investing.com South Africa
FEMY SEC FilingsFEMASYS INC 10-K, 10-Q, 8-K Forms - Stock Titan
FEMASYS (FEMY) COO awarded 150,000 stock options at $0.38 exercise price - Stock Titan
Femasys (FEMY) COO John Canning discloses ownership of 30,000 shares - Stock Titan
Femasys Names John Canning as New Chief Operating Officer - TipRanks
Femasys Inc. Appoints John Canning as Chief Operating Officer, Effective March 30, 2026 - marketscreener.com
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth - bitget.com
Femasys names John Canning as chief operating officer - Investing.com
Femasys names John Canning as Chief Operating Officer - TradingView
Veteran MedTech leader John Canning joins Femasys (NASDAQ: FEMY) as COO - Stock Titan
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update - The Manila Times
Femasys earnings beat by $0.12, revenue fell short of estimates - ca.investing.com
Femasys 2025 10-K: Revenue $2.29M, Net loss per share $(0.47) - TradingView — Track All Markets
Femasys (NASDAQ: FEMY) advances FemBloc and FemaSeed women’s health platform - Stock Titan
Femasys Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Femasys 2025 sales jump on FemBloc demand - TradingView — Track All Markets
Femasys (NASDAQ: FEMY) details 2025 results and FemBloc FINALE trial - Stock Titan
Femasys Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
John Charles Canning Net Worth (2026) - GuruFocus
FEMY Should I Buy - Intellectia AI
Femasys (FEMY) price target decreased by 17.74% to 4.34 - MSN
Femasys (FEMY) CFO receives 34,122 Series D-1 warrants at $0.58 - Stock Titan
Femasys (NASDAQ: FEMY) director awarded 34,122 Series D-1 warrants - Stock Titan
Board seeks reverse split, Nasdaq‑rule approval for issuances (FEMY) - Stock Titan
Femasys (NASDAQ: FEMY) director discloses notes, warrants and share stake - Stock Titan
Femasys Inc. Enters Omnibus Amendment and Issues Series D-1 Warrants – SEC 8-K Filing March 2026 - Minichart
Femasys amends warrants and notes, appoints new director to board By Investing.com - Investing.com India
Femasys amends warrants and notes, appoints new director to board - Investing.com
Femasys (NASDAQ: FEMY) director receives stock options for 35,200 shares - Stock Titan
Femasys Amends Financing Terms and Issues New Warrants - TipRanks
Femasys enters omnibus amendment and consent agreement on March 19, 2026SEC filing - MarketScreener
Femasys Enters Omnibus Amendment And Consent Agreement On March 19, 2026SEC Filing - TradingView
Femasys Amends Notes and Warrants; Issues 16.38M New Warrants at $0.58 to Holders - TradingView
Femasys (FEMY) grants 16.4M Series D-1 warrants and appoints new independent director - Stock Titan
Femasys Inc. announced that it has received $12 million in funding - marketscreener.com
Femasys appoints anesthesiologist to board of directors By Investing.com - Investing.com South Africa
PharmaCyte Biotech (PMCB) logs neutral Form 4 as 10% FEMASYS (FEMY) owner - Stock Titan
Femasys (NASDAQ: FEMY) director Joshua Silverman files neutral Form 4 - Stock Titan
PharmaCyte Biotech (FEMY) reports 7.87% stake including warrants - Stock Titan
Femasys Inc. Appoints Dr. Kenneth D. Eichenbaum to Board of Directors - marketscreener.com
Femasys appoints anesthesiologist to board of directors - Investing.com
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors - Bitget
Femasys Inc. Appoints Kenneth D. Eichenbaum, M.D., M.S.E., to Board of Directors - Quiver Quantitative
Femasys Inc Stock (FEMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.06%
1.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):